Clinical Trial

A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
A Phase 1/2, open-label study of a modified interleukin-2 fusion protein (IOV 3001) in participants with previously treated, unresectable or metastatic melanoma who will receive lifileucel.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-04-15; most recent amendment 2026-06-11.
Trial Details
NCT Number NCT06940739
Lead Sponsor Iovance Biotherapeutics, Inc.
Conditions Unresectable Melanoma, Metastatic Melanoma, Ocular Melanoma
Enrollment 42 participants
Start Date 2025-03-11
Primary Completion 2032-06 (estimated)
Study Completion 2032-07 (estimated)
Updated on ClinicalTrials.gov 2026-06-15